NCT07275463 is a Phase 2 clinical trial of [99mTc]Tc-DB8 in Primary Breast Cancer, sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences.

Who is sponsoring NCT07275463?

NCT07275463 is sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences.

What drugs are being tested in NCT07275463?

Interventions in NCT07275463: [99mTc]Tc-DB8.

What condition does NCT07275463 study?

NCT07275463 studies Primary Breast Cancer.

Is NCT07275463 still recruiting?

NCT07275463 is currently enrolling by invitation. Last updated 22 December 2025.

Last reviewed 2025-12-22 · How we verify

NCT07275463

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

[99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression

ENROLLING BY INVITATION Phase 2 Last updated 22 December 2025

What this trial tests

Phase 2 trial testing [99mTc]Tc-DB8 in Primary Breast Cancer in 40 participants. Enrolling by invitation.

Timeline

1 October 2025

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	Tomsk National Research Medical Center of the Russian Academy of Sciences
Phase	Phase 2
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	40
Start date	1 October 2025
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across Russia

Drugs / interventions tested

[99mTc]Tc-DB8 — full drug profile →

Conditions studied

Primary Breast Cancer — all drugs for Primary Breast Cancer →

Sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Who can join

Adults 18 to 80, female only, with Primary Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study should evaluate the \[99mTc\]Tc-DB8 accumulation in primary tumour of breast cancer patients with positive and negative estrogen receptor expression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Tomsk National Research Medical Center of the Russian Academy of Sciences trials

Trials by the same sponsor.

NCT07457541 — Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI · Phase 1 · active not recruiting
NCT07475390 — 99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging · NA · active not recruiting
NCT07292571 — Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107 · Phase 2 · enrolling by invitation
NCT07018895 — Personalized Hypoxic-hyperoxic Preconditioning in Elderly People · NA · completed
NCT06759259 — Mannitol Administration for Delerium Prevention · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07275463 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tomsk National Research Medical Center of the Russian Academy of Sciences
Last refreshed: 22 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07275463.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing